Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer

Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer

Androgen deprivation therapy is the cornerstone of prostate cancer therapy. Recent studies have revealed an association between androgen deprivation therapy and cardiovascular adverse effects such as myocardial infarction and stroke. This review summarizes the available research on the cardiovascula...

Full description

Bibliographic Details
Main Authors:	James Fradin, Felix J. Kim, Grace L. Lu-Yao, Eugene Storozynsky, William K. Kelly
Format:	Article
Language:	English
Published:	MDPI AG 2023-04-01
Series:	Cancers
Subjects:	androgen deprivation therapy prostate cancer cardiovascular disease racial disparities
Online Access:	https://www.mdpi.com/2072-6694/15/8/2316

Similar Items

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
by: Giovanni Corona, et al.
Published: (2021-07-01)

Impact of androgen deprivation therapy on cognitive function in men with prostate cancer
by: Yutaka Yamamoto, et al.
Published: (2024-03-01)

Influence of Baseline Cardiovascular Comorbidities on Mortality after Androgen Deprivation Therapy for Metastatic Prostate Cancer
by: Szu-Yuan Wu, et al.
Published: (2020-01-01)

Cancer Therapy–Related Cardiac Dysfunction in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
by: Dong‐Yi Chen, et al.
Published: (2023-10-01)

External radiotherapy for prostate cancer with or without androgen deprivation: Geneva, 1991 to 2004
by: R Miralbell, et al.
Published: (2009-09-01)

Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer
by: Gabriela Silvia Gheorghe, et al.
Published: (2021-08-01)

Cardiometabolic and Skeletal Risk Factors in Black Men with Prostate Cancer Starting Androgen Deprivation Therapy
by: Orvar Gunnarsson, et al.
Published: (2015-04-01)

The Influence of Androgen Deprivation Therapy on Prostate Size and Voiding Symptoms in Prostate Cancer Patients in Korea
by: Hoon Choi, et al.
Published: (2016-12-01)

Risk factors for bone loss with prostate cancer in Korean men not receiving androgen deprivation therapy
by: Sun-Ouck Kim, et al.
Published: (2009-04-01)

Association between Androgen Deprivation Therapy and Risk of Dementia in Men with Prostate Cancer
by: Jui-Ming Liu, et al.
Published: (2021-07-01)

A Comprehensive Review of Androgen Deprivation Therapy and Immunotherapy on Prostate Cancer
by: ZHU Hui, et al.
Published: (2019-10-01)

Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues
by: Aditya Bagrodia, et al.
Published: (2009-01-01)

Exercise Adherence in Men with Prostate Cancer Undergoing Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis
by: Kellie Toohey, et al.
Published: (2022-05-01)

Biomarkers of Response to Neoadjuvant Androgen Deprivation in Localised Prostate Cancer
by: Maree Pechlivanis, et al.
Published: (2021-12-01)

Incidence of prostate cancer in transgender women undergoing androgen deprivation therapy: A review
by: Saurabh Tyagi, et al.
Published: (2023-01-01)

Androgen deprivation therapy and the risk of subsequent keratitis
by: Dai-Wei Liu, et al.
Published: (2021-01-01)

Impact of Androgen Deprivation Therapy on Cardiovascular Outcomes in Prostate Cancer
by: Laurence Klotz, et al.
Published: (2022-07-01)

Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer—time for a rethink?
by: Sonja Cabarkapa, et al.
Published: (2018-03-01)

The impact of androgen deprivation therapy on the lipid profile in patients with prostate carcinoma
by: Niraj Kumar, et al.
Published: (2022-06-01)

Androgen deprivation therapy and risk of cognitive dysfunction in men with prostate cancer: is there a possible link?
by: Myungsun Shim, et al.
Published: (2022-03-01)

Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients: a nationwide lithuanian population-based cohort study
by: Justinas Jonušas, et al.
Published: (2022-12-01)

Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots
by: Per-Anders Abrahamsson
Published: (2017-10-01)

Risk of ischemic stroke in patients with prostate cancer receiving androgen deprivation therapy in Taiwan
by: Kuang-Ming Liao, et al.
Published: (2019-12-01)

<i>NRG1</i> Genetic Variant Influences the Efficacy of Androgen-Deprivation Therapy in Men with Prostate Cancer
by: Shu-Pin Huang, et al.
Published: (2021-05-01)

The castration level of testosterone and hormonal resistance of prostate cancer in androgen deprivation therapy
by: I. G. Rusakov, et al.
Published: (2020-12-01)

Survival and mortality of elderly men with localized prostate cancer managed with primary androgen deprivation therapy or by primary observation
by: Heikki Seikkula, et al.
Published: (2020-03-01)

No increased risk of psoriasis in patients receiving androgen deprivation therapy for prostate cancer: a 17-year population-based study
by: Liu JM, et al.
Published: (2018-09-01)

Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients
by: Yue Wang, et al.
Published: (2017-01-01)

Impact of neoadjuvant androgen deprivation therapy on magnetic resonance imaging features in prostate cancer before radiotherapy
by: Ulrika Björeland, et al.
Published: (2021-01-01)

Androgen deprivation therapy and depression in the prostate cancer patients: review of risk and pharmacological management
by: Abdulrahman Alwhaibi, et al.
Published: (2022-12-01)

Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration‐resistant prostate cancer: AFTERCAB study
by: Hiroji Uemura, et al.
Published: (2022-01-01)

Effect of Androgen Deprivation Therapy on the Results of PET/CT with 18F-Fluciclovine in Patients with Metastatic Prostate Cancer
by: Tore Bach-Gansmo, et al.
Published: (2022-06-01)

Integrating diet and exercise into care of prostate cancer patients on androgen deprivation therapy
by: Moyad MA, et al.
Published: (2016-08-01)

Enhancing Androgen Deprivation Therapy (ADT) integration in prostate cancer: Insights for Stereotactic Body Radiotherapy (SBRT) and brachytherapy modalities
by: A. Gomez-Iturriaga, et al.
Published: (2024-03-01)

Racial Distribution of Neighborhood-Level Social Deprivation in a Retrospective Cohort of Prostate Cancer Survivors
by: Oluwole Adeyemi Babatunde, et al.
Published: (2022-10-01)

Cardiovascular Complications in Patients with Prostate Cancer: Potential Molecular Connections
by: Sooraj Kakkat, et al.
Published: (2023-04-01)

Relationship between Androgen Deprivation Therapy and Abdominal Adipose Tissue
by: Federico Greco, et al.
Published: (2022-12-01)

Oligometastatic Prostate Cancer: A Comparison between Multimodality Treatment vs. Androgen Deprivation Therapy Alone
by: Francesco A. Mistretta, et al.
Published: (2022-05-01)

Identification of the Transcription Factor Relationships Associated with Androgen Deprivation Therapy Response and Metastatic Progression in Prostate Cancer
by: Nitya V. Sharma, et al.
Published: (2018-10-01)

Effects of androgen deprivation on brain function in prostate cancer patients – a prospective observational cohort analysis
by: Chao Herta H, et al.
Published: (2012-08-01)